Mody MD, Rocco JW, Yom SS, Haddad RI, Saba NF. Head and neck cancer. Lancet. 2021;398(10318):2289–99.

Article  PubMed  Google Scholar 

Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90(11):824–32.

Article  CAS  PubMed  Google Scholar 

Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53(15):3579–84.

CAS  PubMed  Google Scholar 

Zhu X, Zhang F, Zhang W, He J, Zhao Y, Chen X. Prognostic role of epidermal growth factor receptor in head and neck cancer: a meta-analysis. J Surg Oncol. 2013;108(6):387–97.

Article  PubMed  Google Scholar 

Xu MJ, Johnson DE, Grandis JR. EGFR-targeted therapies in the post-genomic era. Cancer Metastasis Rev. 2017;36(3):463–73.

Article  PubMed  PubMed Central  Google Scholar 

Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.

Article  CAS  PubMed  Google Scholar 

Pignon JP, le Maître A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14.

Article  PubMed  Google Scholar 

Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vokes EE, Agrawal N, Seiwert TY. HPV-associated head and neck cancer. J Natl Cancer Inst. 2015;107(12):djv344.

•• Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393(10166):40–50. This reference is of outstanding importance because it validated cisplatin-RT as the standard of care for HPV-positive patients with LA HNSCC.

•• Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393(10166):51–60. This reference is of outstanding importance because it validated cisplatin-RT as the standard of care for HPV-positive patients with LA HNSCC.

Gebre-Medhin M, Brun E, Engström P, Haugen Cange H, Hammarstedt-Nordenvall L, Reizenstein J, et al. ARTSCAN III: a randomized phase III study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer. J Clin Oncol. 2021;39(1):38–47.

Article  CAS  PubMed  Google Scholar 

Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014;32(27):2940–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tao Y, Auperin A, Sire C, Martin L, Khoury C, Maingon P, et al. Improved outcome by adding concurrent chemotherapy to cetuximab and radiotherapy for locally advanced head and neck carcinomas: results of the GORTEC 2007–01 phase III randomized trial. J Clin Oncol. 2018:Jco2017762518.

Mesía R, Henke M, Fortin A, Minn H, Yunes Ancona AC, Cmelak A, et al. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015;16(2):208–20.

Article  PubMed  Google Scholar 

Specenier P, Vermorken JB. CONCERT-1, an additional piece in the puzzle of (bio)-(chemo)-radiation. Ann Transl Med. 2016;4(21):432.

Article  PubMed  PubMed Central  Google Scholar 

Eriksen JG, Maare C, Johansen J, Primdahl H, Evensen JF, Kristensen CA, et al. Evaluation of the EGFR-inhibitor zalutumumab given with primary curative (Chemo) radiation therapy to patients with squamous cell carcinoma of the head and neck: results of the DAHANCA 19 randomized phase 3 trial: definitive management of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2014;88(2):465.

Article  Google Scholar 

Patil VM, Noronha V, Joshi A, Agarwal J, Ghosh-Laskar S, Budrukkar A, et al. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. Cancer. 2019;125(18):3184–97.

Article  CAS  PubMed  Google Scholar 

Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol. 2013;31(11):1415–21.

Article  CAS  PubMed  Google Scholar 

Burtness B, Haddad R, Dinis J, Trigo J, Yokota T, de Souza VL, et al. Afatinib vs. placebo as adjuvant therapy after chemoradiotherapy in squamous cell carcinoma of the head and neck: a randomized clinical trial. JAMA Oncol. 2019;5(8):1170–80.

Article  PubMed  PubMed Central  Google Scholar 

Ahn MJ, D’Cruz A, Vermorken JB, Chen JP, Chitapanarux I, Dang HQ, et al. Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: a literature review. Oral Oncol. 2016;53:10–6.

Article  PubMed  Google Scholar 

Zandberg DP, Cullen K, Bentzen SM, Goloubeva OG. Definitive radiation with concurrent cetuximab vs radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: analysis of the SEER-medicare linked database. Oral Oncol. 2018;86:132–40.

Article  CAS  PubMed  Google Scholar 

Beckham TH, Barney C, Healy E, Wolfe AR, Branstetter A, Yaney A, et al. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer. Int J Cancer. 2020;147(1):107–15.

Article  CAS  PubMed  Google Scholar 

Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2021;22(4):450–62.

Article  CAS  PubMed  Google Scholar 

Machiels J, Tao Y, Burtness B, Tahara M, Rischin D, Alves GV, et al. LBA5- Primary results of the phase III KEYNOTE-412 study: pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). In: OncologyPRO [Internet]. European Society of Medical Oncology (ESMO) Presidential Symposium II: 2022 Sept 11; Paris, France. Annals of Oncology (2022) 33 (suppl_7): S808-S869. https://doi.org/10.1016/annonc/annonc1089. Available from: https://oncologypro.esmo.org/meeting-resources/esmo-congress/primary-results-of-the-phase-iii-keynote-412-study-pembrolizumab-pembro-with-chemoradiation-therapy-crt-vs-placebo-plus-crt-for-locally-advanc.

Mell LK, Torres-Saavedra PA, Wong SJ, Chang SS, Kish JA, Minn A, et al. Radiotherapy with durvalumab vs. cetuximab in patients with locoregionally advanced head and neck cancer and a contraindication to cisplatin: phase II results of NRG-HN004. In: NRG Oncology [Internet]. Paper presented during the Plenary Session at the annual meeting of the American Society for Radiation Oncology: 2022 October 23–25; San Antonio, TX. Available from: https://www.nrgoncology.org/Home/News/Post/nrg-oncology-trial-nrg-hn004-shows-addition-of-durvalumab-to-radiation-does-not-improve-outcomes-over-cetuximab-for-head-neck-squamous-cell-carcinoma-patients-with-a-contraindication-to-cisplatin-highlights-need-for-further-research.

Bourhis J, Sire C, Tao Y, Wannevich M, Auperin A, Sun X, et al. LBA38 Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015–01 “PembroRad” randomized trial. European Society of Medical Oncology: 2020 Sept 01. Annals of Oncology (2020) 31 (suppl_4): S1168. Available from: https://www.annalsofoncology.org/article/S0923-7534(20)42350-6/fulltext.

Bourhis, J, Tao, Y, Sun, X, Saada-Bouzid, E, Even, C, Auperin, A, et al. LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial. European Society of Medical Oncology: 2021 Sept 01. Annals of Oncology (2021) 32 (suppl_5): S1310. Available from: https://www.annalsofoncology.org/article/S0923-7534(21)04416-1/fulltext.

Caudell JJ, Gillison ML, Maghami E, Spencer S, Pfister DG, Adkins D, et al. NCCN Guidelines® insights: head and neck cancers, Version 1.2022. J Natl Compr Canc Netw. 2022;20(3):224–34.

Article  PubMed  Google Scholar 

Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.

Article  CAS  PubMed  Google Scholar 

Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013;14(8):697–710.

Article  CAS  PubMed  Google Scholar 

Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol. 2013;31(11):1405–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009;27(11):1864–71.

Article  CAS  PubMed  Google Scholar 

Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015;16(5):583–94.

Article  CAS  PubMed  Google Scholar 

Guo Y, Ahn MJ, Chan A, Wang CH, Kang JH, Kim SB, et al. Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial. Ann Oncol. 2019;30(11):1831–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22(1):77–85.

Article  CAS  PubMed  Google Scholar 

de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, et al. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012;18(8):2336–43.

Article  PubMed  PubMed Central  Google Scholar 

Abdul Razak AR, Soulières D, Laurie SA, Hotte SJ, Singh S, Winquist E, et al. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol. 2013;24(3):761–9.

Article  CAS  PubMed  Google Scholar 

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67.

Article  PubMed